Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD
Roflumilast is a selective phosphodiesterase 4 inhibitor which has been licensed in the European Union since 2010 and in Switzerland since November 2011 as an add-on treatment for patients with chronic obstructive pulmonary disease (COPD) in GOLD (Global Initiative for Chronic Obstructive Lung...
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2012-07-01
|
| Sraith: | Swiss Medical Weekly |
| Ábhair: | |
| Rochtain ar líne: | https://www.smw.ch/index.php/smw/article/view/1535 |